Popular
Ready, Set, Act! Opportunities to Address Persistent Unmet Needs in Patients With HFrEF: A Case-Based Discussion
CME/CEReady, Set, Act! Opportunities to Address Persistent Unmet Needs in Patients With HFrEF: A Case-Based Discussion
0.25 creditsINFINITY in Focus: Translating New Nonsteroidal MRA Evidence Into Cardiorenal Practice
NephrologyINFINITY in Focus: Translating New Nonsteroidal MRA Evidence Into Cardiorenal Practice
Hypopigmentation in Atopic Dermatitis Patients with Skin of Color
Dermatology Hub: Neuroimmune NetworkHypopigmentation in Atopic Dermatitis Patients with Skin of Color
When Skin and Itch Do Not Match in Atopic Dermatitis
Dermatology Hub: Neuroimmune NetworkWhen Skin and Itch Do Not Match in Atopic Dermatitis
Ambulatory Monitoring Approaches for PSVT: Which One and When?
MinuteCE®Ambulatory Monitoring Approaches for PSVT: Which One and When?
1.00 program creditsContinuous Glucose and Ketone Monitoring: Making Smarter Decisions in Diabetes
CME/CEContinuous Glucose and Ketone Monitoring: Making Smarter Decisions in Diabetes
1.00 credits
Programs
- Virtual Event
Multiple dates available
Bridging Obesity and MASLD Through Metabolic Dysfunction
INFINITY in Focus: Translating New Nonsteroidal MRA Evidence Into Cardiorenal Practice
NephrologyINFINITY in Focus: Translating New Nonsteroidal MRA Evidence Into Cardiorenal Practice
- CME/CE In-Person & Virtual Event
October 19, 2026
Nashville, TennesseeFrom Fragmented Symptoms to Structured Care: Advancing Menopause Management in Primary Practice
FINE-ONE Across the Ages: Evaluating nsMRA Evidence in CKD and Type 1 Diabetes
Diabetes and EndocrinologyFINE-ONE Across the Ages: Evaluating nsMRA Evidence in CKD and Type 1 Diabetes
Ambulatory Monitoring Approaches for PSVT: Which One and When?
MinuteCE®Ambulatory Monitoring Approaches for PSVT: Which One and When?
1.00 program creditsACACIA-HCM: What Do the Phase 3 Results Show?
CardiologyACACIA-HCM: What Do the Phase 3 Results Show?
Clinical Practice
- CME/CE In-Person & Virtual Event
December 5, 2026
Scottsdale, ArizonaSpotlight on B7-H3 ES-SCLC: Applying ADC Evidence in Real-World Practice
The Next Frontier: Addressing Persistent Cognitive Impairment in Bipolar Disorder
MinuteCE®The Next Frontier: Addressing Persistent Cognitive Impairment in Bipolar Disorder
0.50 program creditsHypoparathyroidism – The Critical Role of Genetics in Your Differential Diagnosis
CME/CEHypoparathyroidism – The Critical Role of Genetics in Your Differential Diagnosis
0.75 creditsClinical Evidence for Anti-CD38–Based Frontline Regimens in Transplant-Eligible Patients With Multiple Myeloma
MinuteCE®Clinical Evidence for Anti-CD38–Based Frontline Regimens in Transplant-Eligible Patients With Multiple Myeloma
0.75 program creditsRecurrence as the Rule: BD Symptoms Persist and Cycle
MinuteCE®Recurrence as the Rule: BD Symptoms Persist and Cycle
0.50 program creditsEmerging Perspectives: The Potential Role of Xanomeline Trospium Across the Bipolar Spectrum
MinuteCE®Emerging Perspectives: The Potential Role of Xanomeline Trospium Across the Bipolar Spectrum
0.50 program credits
Doctors Lounge
Humanoids in Healthcare: Extending the Reach of Surgical Expertise
The ConvergenceHumanoids in Healthcare: Extending the Reach of Surgical Expertise
Engaging Patients and Caregivers About Digital Therapeutics
Medical Industry FeatureEngaging Patients and Caregivers About Digital Therapeutics
Advancing ATTR-CM Identification: Early Findings from TRACE-AI
Heart MattersAdvancing ATTR-CM Identification: Early Findings from TRACE-AI
Earlier Detection, Smarter Prevention: AI-Powered Alzheimer's Care
The ConvergenceEarlier Detection, Smarter Prevention: AI-Powered Alzheimer's Care
The Changing Landscape of CRC Screening and Prevention
On the Frontlines of Colorectal CancerThe Changing Landscape of CRC Screening and Prevention
Inside Medical Affairs: MSL Insights on AI, Strategy, and Impact
MAPSChatsInside Medical Affairs: MSL Insights on AI, Strategy, and Impact
CME
Redefining Endocrine Therapy: The Evidence Behind Oral SERDs and PROTAC ER Degraders
MinuteCE®Redefining Endocrine Therapy: The Evidence Behind Oral SERDs and PROTAC ER Degraders
0.50 program creditsClinical Evidence for Anti-CD38–Based Frontline Regimens in Transplant-Ineligible Patients With Multiple Myeloma
MinuteCE®Clinical Evidence for Anti-CD38–Based Frontline Regimens in Transplant-Ineligible Patients With Multiple Myeloma
0.75 program creditsNavigating Treatment Selection After First-line CDK4/6 Inhibitor Progression
MinuteCE®Navigating Treatment Selection After First-line CDK4/6 Inhibitor Progression
0.50 program credits- MinuteCE®
Oral SERDs and PROTACs in ER+/HER2− mBC: Testing Smarter, Treating Better
0.50 credits 4 episodes Case Consult: Implementing Anti-CD38–Based Frontline Regimens in Transplant-Ineligible Patients
MinuteCE®Case Consult: Implementing Anti-CD38–Based Frontline Regimens in Transplant-Ineligible Patients
0.75 program creditsTranslating Safety Data Into Practice: Effective AE Management in Oral SERD and PROTAC Regimens
MinuteCE®Translating Safety Data Into Practice: Effective AE Management in Oral SERD and PROTAC Regimens
0.50 program credits
Industry Feature
Helping Patients Stay on Track With Collaborative LDL-C Care
Medical Industry FeatureHelping Patients Stay on Track With Collaborative LDL-C Care
Taking Action in Friedreich Ataxia From Diagnosis to Treatment
Medical Industry FeatureTaking Action in Friedreich Ataxia From Diagnosis to Treatment
Understanding Obesity: From Adiposity to Multi-Organ Impact
Medical Industry FeatureUnderstanding Obesity: From Adiposity to Multi-Organ Impact
Centanafadine for Management of Executive Dysfunction and Emotional Dysregulation in Adults with ADHD
Innovations In MedicineCentanafadine for Management of Executive Dysfunction and Emotional Dysregulation in Adults with ADHD
Navigating ASCVD and Pancreatitis Risk in Severe Hypertriglyceridemia
Innovations In MedicineNavigating ASCVD and Pancreatitis Risk in Severe Hypertriglyceridemia
What Is on the ‘HERIZON’ in 1L HER2+ Gastroesophageal Adenocarcinoma?
Medical Industry FeatureWhat Is on the ‘HERIZON’ in 1L HER2+ Gastroesophageal Adenocarcinoma?